Adaltis Inc. Provides Update on its Activities and Financing Requirements

MONTREAL, QUEBEC, Apr 29 (MARKET WIRE) --
Adaltis Inc. (TSX: ADS), an international in vitro diagnostic (IVD)
company wishes to communicate recent changes in its key leadership team
and recent developments in its business prospects.

The Corporation previously announced in February 2009 the appointment of
Mr. Peter Bambic as President and Chief Executive Officer of Adaltis. Mr.
Bambic was formerly with Ortho Clinical Diagnostics (OCD), a Johnson &
Johnson company, and has over 25 years of sales and marketing experience
in the IVD industry; particularly in the emerging markets that comprise
the platform for Adaltis' planned revenue growth. As Managing Director
for the Asia-Pacific Region, Mr. Bambic led OCD's push into the China
market and has over 10 years experience doing business in that country.
Mr. Bambic is based in Shanghai.

Subsequently, in March 2009, the Corporation announced the appointment of
Mr. David Gardner as Executive Vice President and Chief Financial Officer
of Adaltis, reporting to Mr. Bambic. Mr. Gardner was formerly Corporate
Controller for Adaltis and will be dividing his time between the
Corporation's Montreal and Shanghai headquarters.

In 2008, Adaltis announced the voluntary slowing down of sales for the
Eclectica(TM) bench-top, integrated IVD system to focus on several
market-driven product improvements. During 2008, the Corporation
identified, designed and implemented improvements to the system,
including new operating software, and in October 2008 announced the
controlled re-launch of Eclectica(TM) into certain markets, namely China,
Mexico and Italy. Over the past several months the Eclectica(TM) has
performed well in customers' laboratories and Adaltis expects to
re-launch a broad sales effort of the system in the second half of 2009.

The re-launch of Eclectica(TM) has taken longer than originally
anticipated due to the decision to implement a controlled re-launch
rather than a full market re-launch. This, coupled with a downturn in
economic activity worldwide and the number of credit related issues, has
resulted in a significant depletion of the Corporation's cash resources.

In light of the above, the significant volatility in the capital markets
and the current challenges for companies such as Adaltis to access
markets for financing, Adaltis is in discussion with certain parties to
provide additional financing in order to ensure continuing operations
beyond May 2009. No definitive agreements with potential investors have
been reached yet and there can be no assurance that such agreements will
be reached.

There can be no assurance that any transaction will be concluded or that
Adaltis will be able to continue as a going concern without successfully
raising additional financing through borrowings, share issuances, sale of
assets or otherwise. The outcome of these matters is in large part beyond
the Corporation's control and will likely be subject to a number of
conditions, some of which may not be favourable to the Corporation.

Caution Concerning Forward-Looking Statements

Although this is not an exhaustive list, we caution you that statements
concerning the following subjects in particular are, or are likely to be,
forward-looking statements: the impact of our efforts to concentrate our
management team in China and focus on our key IVD product lines, our
expectations regarding the improvements to and the re-launch and the
commercial prospects of Eclectica(TM), the impact of our accelerated
streamlining efforts in Europe and elsewhere, the registration of our
products in China, the short and long-term implications and the value of
our holdings of asset-backed commercial paper, and any statements
concerning the successful development, market penetration and sales of
our products.

Important factors that could cause differences include factors, such as
obtaining regulatory registrations, affecting our ability to achieve our
strategy in China and other emerging markets, the successful and timely
completion of our ongoing research and development efforts in particular
related to Eclectica(TM), the launch of new products, the uncertainties
of market factors and regulatory processes to which our business is
subject, the ability to recover the value of our holdings of asset-backed
commercial paper following the restructuring of the asset-backed
commercial paper market, and the availability and terms of any financing.
For additional information with respect to certain of these and other
factors, refer to our Annual Information Form under the heading "Risk
Factors" filed with the Canadian securities commissions.

The forward-looking statements contained in this press release represent
the expectations of Adaltis Inc. and its subsidiaries as at the date
hereof and accordingly are subject to change after such date. However,
Adaltis Inc. and its subsidiaries expressly disclaim any intention or
obligation to update or revise any forward-looking statements, whether as
a result of new information, future events or otherwise, except as
required by applicable law.

About Adaltis Inc.

Adaltis is an international in vitro diagnostic company with a mission to
become a leading provider of in vitro diagnostic products in emerging
markets, with a particular focus on China.

With the strategic advantage of its "state of the art" reagent
manufacturing facility located in Shanghai, China, a complete IVD product
offering targeting emerging markets, and a strong international sales and
distribution platform, Adaltis is able to manufacture high-quality
products in a low-cost GMP environment, in order to service existing
markets in Europe, while providing a platform to penetrate the
high-growth Chinese in vitro diagnostic market.

Adaltis is headquartered in Montreal, with offices in China, Italy,
Mexico and other parts of the world.

Contacts:
Adaltis Inc.
David Gardner
Executive Vice President and Chief Financial Officer
514-335-9922, ext. 228
david.gardner@adaltis.com

Copyright 2009, Market Wire, All rights reserved.

-0-